Correlates of antiretroviral adherence and viral load among transgender women living with HIV

Sevelius, Jae; Saberi, Parya; Johnson, Mallory O.

doi:10.1080/09540121.2014.896451

Cited by 71 publications

(57 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Given our results that current HT users may report higher rates of HT or ART adherence, our findings support previous data, 29,30 suggesting that gender-affirming healthcare, including clinical integration of HT and ART services, may improve engagement in HIV care for TW.…”

Section: Braun Et Alsupporting

confidence: 81%

“…Considering the recent findings that (1) TW may have suboptimal ART adherence, 28,29 and (2) higher HT adherence and access to other transgender-specific healthcare factors is associated with higher ART adherence, 30 opportunities exist to utilize this synergy to ensure greater participation in HIV care by TW. Given our results that current HT users may report higher rates of HT or ART adherence, our findings support previous data, 29,30 suggesting that gender-affirming healthcare, including clinical integration of HT and ART services, may improve engagement in HIV care for TW.…”

Section: Braun Et Almentioning

confidence: 99%

See 1 more Smart Citation

Transgender Women Living with HIV Frequently Take Antiretroviral Therapy and/or Feminizing Hormone Therapy Differently Than Prescribed Due to Drug–Drug Interaction Concerns

et al. 2017

View full text Add to dashboard Cite

Purpose: Both hormone therapy (HT) and antiretroviral therapy (ART) can be lifesaving for transgender women (TW) living with HIV, but each has side effects and potential drug-drug interactions (DDI). We assessed how concerns about HT-ART interactions affect treatment adherence. Methods: This study used a cross-sectional survey of TW (n = 87) in Los Angeles, CA. Results: Fifty-four percent were living with HIV; 64% used HT. Only 49% of TW living with HIV discussed ART-HT DDI with their provider; 40% reported not taking ART (12%), HT (12%), or both (16%) as directed due to DDI concerns. Conclusion: Imperfect HT/ART use and limited provider communication suggests a need for improved HT-ART integration.

show abstract

Section: Braun Et Alsupporting

confidence: 81%

Section: Braun Et Almentioning

confidence: 99%

Transgender Women Living with HIV Frequently Take Antiretroviral Therapy and/or Feminizing Hormone Therapy Differently Than Prescribed Due to Drug–Drug Interaction Concerns

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Some barriers to PrEP effectiveness among trans women have already been identified, such as the complex and heterogeneous psychosocial motivations for engaging in risk compensation among trans women (Golub, 2014), as well as many correlates to poor PrEP adherence (Golub, et al, 2013). Particular attention should also be paid to unique barriers that trans women may experience while obtaining access to PrEP, such as gender discrimination, transphobia, and violence, which have been observed to play an important role in reducing acceptability of and access to other HIV testing, preventive and treatment services (Golub & Gamarel, 2013; Golub et al, 2013; Sevelius, Patouhas, Keatley, & Johnson, 2014; Sevelius, Saberi, & Johnson, 2014). …”

Section: Discussionmentioning

confidence: 99%

Inclusion of trans women in pre-exposure prophylaxis trials: a review

et al. 2014

View full text Add to dashboard Cite

Trans women are at high-risk of HIV infection. We conducted a review to determine the extent to which trans women were eligible for inclusion in and enrolled into pre-exposure prophylaxis (PrEP) efficacy trials. Out of seven trials analyzing PrEP efficacy, we found that trans women comprised only 1.2% of one trial, and 0.2% of total trial enrollments. Although an additional PrEP trial to determine efficacy among trans women may not be warranted, further research is needed to determine the effectiveness of PrEP in this marginalized population, through observational and feasibility studies. These studies should focus on unique barriers that trans women may experience while obtaining access to PrEP, such as gender discrimination, transphobia, and violence.

show abstract

“…Furthermore, multiple studies support that transgender women living with HIV (TWLWH) were less likely to report higher adherence to anti-retroviral therapy (ART) compared to other adults with HIV (Sevelius, Carrico, & Johnson, 2010; Mizuno, Frazier, Huang & Skarbinski, 2015). In TWLWH, ART adherence has been associated with older age, abstinence from alcohol, positive gender affirmation and adherence to hormones (Sevelius, Saberi, & Johnson, 2014). Similarly, in our previous analysis of adherence and symptom experience among adults living with HIV (Gay et al, 2011), we found that our group of TWLWH reported significantly poorer adherence compared to other adults.…”

Section: Introductionmentioning

confidence: 99%

Medication adherence among transgender women living with HIV

2016

View full text Add to dashboard Cite

Medication adherence is linked to health outcomes among adults with HIV infection. Transgender women living with HIV (TWLWH) in the U.S. report suboptimal adherence to medications and are found to have difficulty integrating HIV medication into their daily routine, but few studies explore factors associated with medication adherence among transgender women. Thus, the purpose of this paper is to examine demographic and clinical factors related to self-reported medication adherence among transgender women. This secondary analysis is based on data collected from the Symptom and Genetic Study that included a convenience sample of 22 self-identified transgender women, 201 non-transgender men, and 72 non-transgender women recruited in northern California. Self-reported medication adherence was assessed using the AIDS Clinical Trials Group Adherence Questionnaire. Gender differences in demographic and clinical variables were assessed, as were differences between transgender women reporting high and low adherence. Transgender women had lower adherence to medications compared to non-transgender males and non-transgender females (p=.028) and were less likely to achieve viral suppression (p=.039). Within the transgender group, Black/African Americans reported better adherence than participants who were Whites/Caucasian or other races (p=.009). Adherence among transgender women was unrelated to medication count and estrogen therapy, but consistent with other reports on the HIV population as a whole; transgender women with high adherence were more likely to achieve viral suppression compared to the transgender women with low adherence. Despite the high incidence of HIV infection in the transgender population, few studies focus on TWLWH, either in regard to their adherence to antiretroviral therapies or to their healthcare in general. To address ongoing health disparities, more studies are needed focusing on the transgender population’s continuum of care in HIV therapies.

show abstract

Correlates of antiretroviral adherence and viral load among transgender women living with HIV

Cited by 71 publications

References 29 publications

Transgender Women Living with HIV Frequently Take Antiretroviral Therapy and/or Feminizing Hormone Therapy Differently Than Prescribed Due to Drug–Drug Interaction Concerns

Transgender Women Living with HIV Frequently Take Antiretroviral Therapy and/or Feminizing Hormone Therapy Differently Than Prescribed Due to Drug–Drug Interaction Concerns

Inclusion of trans women in pre-exposure prophylaxis trials: a review

Medication adherence among transgender women living with HIV

Contact Info

Product

Resources

About